Age-Related Macular Degeneration (AMD) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Basel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E are two leading causes of vision loss worldwide.1 Vabysmo targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).2 Vabysmo is the first and only FDA-approved injectable eye medicine...
Source: Roche Investor Update - January 31, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Investor Update - January 31, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Media News - January 31, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Faricimab for nAMD and Diabetic Macular Edema FDA Approves Faricimab for nAMD and Diabetic Macular Edema
The FDA has approved faricimab, a drug with the potential to reduce the number of injections needed to treat diabetic macular edema and neovascular age-related macular degeneration.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 29, 2022 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA Approves Vabysmo (faricimab-svoa) for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration and Diabetic Macular Edema
South San Francisco, CA -- January 28, 2022 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2022 Category: Drugs & Pharmacology Source Type: news
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Basel, 24 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). [1,2] All four studies – which enrolled more than 3,000 people in total – met their primary endpoints, showing that people treated with faricimab up to every four months achieved non-inferior vision gains compare d to aflibercept given every two months. Notably, about half of eligible f...
Source: Roche Media News - January 24, 2022 Category: Pharmaceuticals Source Type: news
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Basel, 24 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). [1,2] All four studies – which enrolled more than 3,000 people in total – met their primary endpoints, showing that people treated with faricimab up to every four months achieved non-inferior vision gains compare d to aflibercept given every two months. Notably, about half of eligible f...
Source: Roche Investor Update - January 24, 2022 Category: Pharmaceuticals Source Type: news
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche ’s phase III trials evaluatingfaricimab inneovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four studies, about half of eligiblefaricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longerReductions in central subfield thickness (CST) and resolution ofintraretinal fluid consistentlyfavouredfaricimab overaflibercept in DME, and meaningful and comparable CST reductions were seen innAMD in the first yearBasel, 24 January 2022 - Roche (SIX...
Source: Roche Investor Update - January 24, 2022 Category: Pharmaceuticals Source Type: news
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche ’s phase III trials evaluatingfaricimab inneovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four studies, about half of eligiblefaricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longerReductions in central subfield thickness (CST) and resolution ofintraretinal fluid consistentlyfavouredfaricimab overaflibercept in DME, and meaningful and comparable CST reductions were seen innAMD in the first yearBasel, 24 January 2022 - Roche (SIX...
Source: Roche Media News - January 24, 2022 Category: Pharmaceuticals Source Type: news
Moorfields Eye Hospital gives woman, 88, UK's first 'bionic eye implant'
A microchip has been implanted into her eye to tackle dry age-related macular degeneration (AMD). (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 21, 2022 Category: Consumer Health News Source Type: news
Woman, 88, gets 'bionic eye implant'
A microchip has been implanted into her eye to tackle dry age-related macular degeneration (AMD). (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 21, 2022 Category: Consumer Health News Source Type: news
Bionic eye implant enables blind UK woman to detect visual signals
Breakthrough offers hope of restoration of sight to people suffering vision loss because of dry AMDAn 88-year-old woman has told of her joy at becoming the first patient in the UK to benefit from a groundbreaking bionic eye implant that enabled her to detect signals for the first time since going blind.The woman from Dagenham suffers from geographic atrophy. The condition is the most common form of dry age-related macular degeneration (AMD), which affects millions of people worldwide and can cause loss of sight.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 21, 2022 Category: Science Authors: Andrew Gregory Health editor Tags: Blindness and visual impairment Health Disability Society Medical research UK news Source Type: news
Eye expert shares two dietary additions that could reduce vision loss by 36 percent
SIGHT loss can be attributed to age-related macular degeneration - a common condition that first affects people in their 50s and beyond. Diet, however, could play a protective role. (Source: Daily Express - Health)
Source: Daily Express - Health - January 16, 2022 Category: Consumer Health News Source Type: news
Year in Review: Bay Area fed its drug habit with FDA approvals
No blockbusters, but the Bay Area's drug-development engine continued to produce a wide range of therapeutics in 2021.
From a drug-implant developed by Genentech Inc. of South San Francisco for people with the eye disease wet age-related macular degeneration to San Mateo-based Myovant Sciences Ltd.'s treatment for women with heavy menstrual bleeding due to severe uterine fibroids, biotech and traditional drug deve lopers continued a long streak of Food and Drug Administration approvals.
This slideshow… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Year in Review: Bay Area fed its drug habit with FDA approvals
No blockbusters, but the Bay Area's drug-development engine continued to produce a wide range of therapeutics in 2021.
From a drug-implant developed by Genentech Inc. of South San Francisco for people with the eye disease wet age-related macular degeneration to San Mateo-based Myovant Sciences Ltd.'s treatment for women with heavy menstrual bleeding due to severe uterine fibroids, biotech and traditional drug deve lopers continued a long streak of Food and Drug Administration approvals.
This slideshow… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 28, 2021 Category: Health Management Authors: Ron Leuty Source Type: news
